Welcome to our dedicated page for BillionToOne news (Ticker: BLLN), a resource for investors and traders seeking the latest updates and insights on BillionToOne stock.
Our selection of high-quality news articles is accompanied by an expert summary from Rhea-AI, detailing the impact and sentiment surrounding the news at the time of release, providing a deeper understanding of how each news could potentially affect BillionToOne's stock performance. The page also features a concise end-of-day stock performance summary, highlighting the actual market reaction to each news event. The list of tags makes it easy to classify and navigate through different types of news, whether you're interested in earnings reports, stock offerings, stock splits, clinical trials, fda approvals, dividends or buybacks.
Designed with both novice traders and seasoned investors in mind, our page aims to simplify the complex world of stock market news. By combining real-time updates, Rhea-AI's analytical insights, and historical stock performance data, we provide a holistic view of BillionToOne's position in the market.
BillionToOne (NASDAQ: BLLN) announced the appointment of Anthony Pagano to its Board of Directors, effective January 1, 2026, and named him Chair of the Audit Committee.
Pagano is currently CFO and Executive Vice President of Genmab since March 2020 and previously joined Genmab in December 2007. During his tenure at Genmab, annual revenues grew from $100M to more than $3B. He began his career at KPMG, served in senior finance roles at NovaDel Pharma, is a Certified Public Accountant, holds a B.S. in Accounting and an M.B.A. from NYU Stern.
Company leaders said Pagano's financial experience will support BillionToOne's growth and governance as it advances its molecular diagnostics strategy.
BillionToOne (NASDAQ: BLLN) reported strong third-quarter 2025 results and issued full-year guidance. Total revenue was $83.5M in Q3 2025, up 117% year-over-year; prenatal revenue was $74.1M (+102%) and oncology revenue was $8.7M (+664%).
Gross margin improved to 70% (vs. 53% prior year); operating income was $9.6M and net income available to common shareholders was $1.5M ($0.10 diluted). The company accessioned 162,900 tests in Q3 and delivered 165,000 tests.
Company raised $314.0M gross proceeds in its IPO and ended September 30, 2025 with approximately $195.2M cash. BillionToOne expects 2025 revenue of $293M–$299M and positive GAAP operating income for Q4 and full-year 2025.
BillionToOne (NASDAQ: BLLN) will release financial results for the third quarter ended September 30, 2025 after market close on Tuesday, December 9, 2025. The company will host a conference call to discuss results at 1:30 PM PT / 4:30 PM ET the same day.
Investors must register to participate in the call before the start time. A live and archived webcast will be available on the company’s Events page at https://investors.billiontoone.com/.
BillionToOne (NASDAQ: BLLN) closed an upsized initial public offering on Nov 7, 2025, selling 5,233,765 shares of Class A common stock, which includes full exercise of the underwriters’ option for an additional 682,665 shares.
The public offering price was $60.00 per share, and the aggregate gross proceeds were approximately $314.0 million before underwriting discounts, commissions and estimated offering expenses. BillionToOne began trading on the Nasdaq Global Select Market on Nov 6, 2025 under the ticker BLLN.
BillionToOne (Nasdaq: BLLN) completed an upsized initial public offering of 4.6 million shares of Class A common stock at $60 per share, generating approximately $273.1 million in aggregate gross proceeds. The shares began trading on the Nasdaq Global Select Market on November 6, 2025, with the offering expected to close on November 7, 2025.
Gunderson Dettmer represented BillionToOne across multiple financings from Series A through late-stage rounds and advised on the public listing; J.P. Morgan, Piper Sandler, Jefferies and William Blair acted as joint book-running managers, with Stifel, Wells Fargo Securities and BTIG also serving as book-running managers.
BillionToOne (Nasdaq: BLLN) priced an upsized initial public offering of 4,551,100 shares of Class A common stock at $60.00 per share, with expected gross proceeds of approximately $273.1 million before underwriting discounts and expenses.
The underwriters have a 30-day option to purchase up to an additional 682,665 shares at the IPO price. Shares are expected to begin trading on the Nasdaq Global Select Market on November 6, 2025, and the offering is expected to close on November 7, 2025, subject to customary closing conditions.
BillionToOne (NASDAQ: BLLN) launched the roadshow for a proposed initial public offering of 3,846,000 shares of Class A common stock, with a 30-day underwriter option to purchase up to 576,900 additional shares.
The initial public offering price is currently expected to be between $49.00 and $55.00 per share. BillionToOne has applied to list its Class A common stock on the Nasdaq Global Select Market under the ticker BLLN. J.P. Morgan, Piper Sandler, Jefferies and William Blair are joint book-running managers.
A registration statement on Form S-1 has been filed with the SEC but has not yet become effective; offers or sales may not occur before effectiveness.
FAQ
What is the current stock price of BillionToOne (BLLN)?
What is the market cap of BillionToOne (BLLN)?
